Resurgence of persisting non-cultivable Borrelia burgdorferi following antibiotic treatment in mice.
The agent of Lyme borreliosis, Borrelia burgdorferi, evades host immunity and establishes persistent infections in its varied mammalian hosts. This persistent biology may pose challenges to effective antibiotic treatment. Experimental studies in dogs, mice, and non-human primates have found persistence of B. burgdorferi DNA following treatment with a variety of antibiotics, but persisting spirochetes are non-cultivable. Persistence of B. burgdorferi DNA has been documented in humans following treatment, but the significance remains unknown. The present study utilized a ceftriaxone treatment regimen in the C3H mouse model that resulted in persistence of non-cultivable B. burgdorferi in order to determine their long-term fate, and to examine their effects on the host. Results confirmed previous studies, in which B. burgdorferi could not be cultured from tissues, but low copy numbers of B. burgdorferi flaB DNA were detectable in tissues at 2, 4 and 8 months after completion of treatment, and the rate of PCR-positive tissues appeared to progressively decline over time. However, there was resurgence of spirochete flaB DNA in multiple tissues at 12 months, with flaB DNA copy levels nearly equivalent to those found in saline-treated mice. Despite the continued non-cultivable state, RNA transcription of multiple B. burgdorferi genes was detected in host tissues, flaB DNA was acquired by xenodiagnostic ticks, and spirochetal forms could be visualized within ticks and mouse tissues by immunofluorescence and immunohistochemistry, respectively. A number of host cytokines were up- or down-regulated in tissues of both saline- and antibiotic-treated mice in the absence of histopathology, indicating host response to the presence of non-cultivable, despite the lack of inflammation in tissues.
Center for Comparative Medicine, Schools of Medicine and Veterinary Medicine, University of California Davis, Davis, California, United States of America.
Emir
E
Hodzic
Center for Comparative Medicine, Schools of Medicine and Veterinary Medicine, University of California Davis, Davis, California, United States of America.
Denise
D
Imai
Center for Comparative Medicine, Schools of Medicine and Veterinary Medicine, University of California Davis, Davis, California, United States of America.
Sunlian
S
Feng
Center for Comparative Medicine, Schools of Medicine and Veterinary Medicine, University of California Davis, Davis, California, United States of America.
Stephen W
SW
Barthold
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D025065:Borrelia burgdorferi / Q000187:drug effects* / Q000502:physiology; D002443:Ceftriaxone / Q000494:pharmacology*; D004269:DNA, Bacterial / Q000235:genetics; D004285:Dogs; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D008193:Lyme Disease / Q000188:drug therapy* / Q000235:genetics / Q000382:microbiology; D051379:Mice; D008809:Mice, Inbred C3H; D016133:Polymerase Chain Reaction; D012008:Recurrence; D013144:Spirochaetales / Q000187:drug effects* / Q000235:genetics; D020525:Xenodiagnosis
D000900:Anti-Bacterial Agents; D004269:DNA, Bacterial; D002443:Ceftriaxone